Liposomal bupivacaine (LB) as part of a periarticular injection protocol continues to be a highly debated topic in total knee arthroplasty (TKA). We evaluated the effect of discontinuing the use of LB in a periarticular protocol on immediate postoperative pain scores, opioid consumption, and objective functional outcomes. On 1 July 2019, we discontinued the use of intraoperative LB as part of a periarticular injection protocol. A consecutive group of patients who received LB as part of the protocol (Protocol 1) and a subsequent group who did not (Protocol 2) were compared. All patients received the same opioid-sparing protocol. Verbal rating scale (VRS) pain scores were collected from our electronic data warehouse and averaged per patient per 12-hour interval. Events relating to the opiate administration were derived as morphine milligram equivalences (MMEs) per patient per 24-hour interval. The Activity Measure for Post-Acute Care (AM-PAC) tool was used to assess the immediate postoperative function.Aims
Methods
Postoperative range of movement (ROM) is an important measure of successful and satisfying total knee arthroplasty (TKA). Reduced postoperative ROM may be evident in up to 20% of all TKAs and negatively affects satisfaction. To improve ROM, manipulation under anaesthesia (MUA) may be performed. Historically, a limited ROM preoperatively was used as the key harbinger of the postoperative ROM. However, comorbidities may also be useful in predicting postoperative stiffness. The goal was to assess preoperative comorbidities in patients undergoing TKA relative to incidence of postoperative MUA. The hope is to forecast those who may be at increased risk and determine if MUA is an effective form of treatment. Prospectively collected data of TKAs performed at our institution’s two hospitals from August 2014 to August 2018 were evaluated for incidence of MUA. Comorbid conditions, risk factors, implant component design and fixation method (cemented vs cementless), and discharge disposition were analyzed. Overall, 3,556 TKAs met the inclusion criteria. Of those, 164 underwent MUA.Aims
Methods
The purpose of this study was to use pharmacogenetics to determine the frequency of genetic variants in our total knee arthroplasty (TKA) patients that could affect postoperative pain medications. Pharmacogenetic testing evaluates patient DNA to determine if a drug is expected to have a normal clinical effect, heightened effect, or no effect at all on the patient. It also predicts whether patients are likely to experience side effects from medicine. We further sought to determine if changing the multimodal programme based on these results would improve pain control or reduce side effects. In this pilot study, buccal samples were collected from 31 primary TKA patients. Pharmacogenetics testing examined genetic variants in genes Aims
Methods
The aim of this study was to determine the general postoperative opioid consumption and rate of appropriate disposal of excess opioid prescriptions in patients undergoing primary unilateral total knee arthroplasty (TKA). In total, 112 patients undergoing surgery with one of eight arthroplasty surgeons at a single specialty hospital were prospectively enrolled. Three patients were excluded for undergoing secondary procedures within six weeks. Daily pain levels and opioid consumption, quantity, and disposal patterns for leftover medications were collected for six weeks following surgery using a text-messaging platform.Aims
Patients and Methods
Adductor canal block (ACB) has emerged as an alternative to femoral nerve block (FNB) for analgesia after total knee arthroplasty (TKA). The optimal duration of maintenance of the ACB is still questionable. The purpose of this study was to compare the analgesic benefits and physiotherapy (PT) outcomes of single-shot ACB to two different regimens of infusion of the continuous ACB, 24-hour and 48-hour infusion. This was a prospective, randomized, unblinded study. A total of 159 American Society of Anesthesiologists (ASA) physical status I to III patients scheduled for primary TKA were randomized to one of three study groups. Three patients did not complete the study, leaving 156 patients for final analysis. Group A (n = 53) was the single-shot group (16 female patients and 37 male patients with a mean age of 63.9 years (Aims
Patients and Methods
The purpose of this study was to evaluate trends in opioid use
after unicompartmental knee arthroplasty (UKA), to identify predictors
of prolonged use and to compare the rates of opioid use after UKA,
total knee arthroplasty (TKA) and total hip arthroplasty (THA). We identified 4205 patients who had undergone UKA between 2007
and 2015 from the Humana Inc. administrative claims database. Post-operative
opioid use for one year post-operatively was assessed using the
rates of monthly repeat prescription. These were then compared between
patients with and without a specific variable of interest and with
those of patients who had undergone TKA and THA.Aims
Materials and Methods
Pain, swelling and inflammation are expected
during the recovery from total knee arthroplasty (TKA) surgery.
The severity of these factors and how a patient copes with them
may determine the ultimate outcome of a TKA. Cryotherapy and compression
are frequently used modalities to mitigate these commonly experienced
sequelae. However, their effect on range of motion, functional testing,
and narcotic consumption has not been well-studied. A prospective, multi-center, randomised trial was conducted to
evaluate the effect of a cryopneumatic device on post-operative
TKA recovery. Patients were randomised to treatment with a cryopneumatic
device or ice with static compression. A total of 280 patients were
enrolled at 11 international sites. Both treatments were initiated
within three hours post-operation and used at least four times per
day for two weeks. The cryopneumatic device was titrated for cooling
and pressure by the patient to their comfort level. Patients were evaluated by physical therapists blinded to the
treatment arm. Range of motion (ROM), knee girth, six minute walk
test (6MWT) and timed up and go test (TUG) were measured pre-operatively,
two- and six-weeks post-operatively. A visual analog pain score
and narcotic consumption was also measured post-operatively. At two weeks post-operatively, both the treatment and control
groups had diminished ROM and function compared to pre-operatively.
Both groups had increased knee girth compared to pre- operatively.
There was no significant difference in ROM, 6MWT, TUG, or knee girth
between the 2 groups. We did find a significantly lower amount of
narcotic consumption (509 mg morphine equivalents) in the treatment
group compared with the control group (680 mg morphine equivalents)
at up to two weeks postop, when the cryopneumatic device was being
used (p <
0.05). Between two and six weeks, there was no difference
in the total amount of narcotics consumed between the two groups.
At six weeks, there was a trend toward a greater distance walked
in the 6MWT in the treatment group (29.4 meters versus 7.9
meters, p = 0.13). There was a significant difference in the satisfaction
scores of patients with their cooling regimen, with greater satisfaction
in the treatment group (p <
0.0001). There was no difference
in ROM, TUG, VAS, or knee girth at six weeks. There was no difference
in adverse events or compliance between the two groups. A cryopneumatic device used after TKA appeared to decrease the
need for
